Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aeglea Biothera
(NQ:
AGLE
)
7.790
USD
UNCHANGED
Streaming Delayed Price
Updated: 7:39 PM EST, Mar 1, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
7.790
Bid (Size)
6.300 (2)
Ask (Size)
8.040 (11)
Prev. Close
7.790
Today's Range
7.790 - 7.790
52wk Range
3.500 - 11.38
Shares Outstanding
21,858,874
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
February 24, 2021
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today...
From
PR Newswire
Aeglea BioTherapeutics Announces Transition of Chief Financial Officer
February 03, 2021
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today...
From
PR Newswire
Performance
YTD
-9.00%
-9.00%
1 Month
+6.86%
+6.86%
3 Month
-9.00%
-9.00%
6 Month
+7.08%
+7.08%
1 Year
+13.23%
+13.23%
More News
Read More
Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021
From
PR Newswire
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
December 17, 2020
From
PR Newswire
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
December 01, 2020
From
PR Newswire
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
November 24, 2020
From
PR Newswire
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
November 17, 2020
From
PR Newswire
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 05, 2020
From
PR Newswire
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
October 26, 2020
From
PR Newswire
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
October 05, 2020
From
PR Newswire
Aeglea BioTherapeutics to Participate in September Investment Conferences
September 02, 2020
From
GlobeNewswire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.